We summarized the long-term efficacy of palliduspallidus internus (GPi) deepbrain stimulation (DBS) for drug-refractory Tourette’s syndrome (TS). METHODS: A retrospective analysis of 13 patients with refractory TS who underwent GPi-DBS in the Department of Neurosurgery at Tiantan Hospital from January 2006 to May 2013 was performed. Patients were assessed for symptom severity preoperatively, at one month postoperatively, and every 6 months with the Yale Global Tic Severity Scale (YGTSS), and for behavior with the Tourette SyndromeCQuality of Life Scale (TSQOL). TSQOL) to assess their behavior and mood. The mean rates of improvement from preoperative baseline status at 1, 6, 12, 18, 24, 30, and 36 months after YGTSS were 11.8%, 20.0%, 26.8%, 36.7%, 44.7%, 49.0%, and 56.7%, respectively. percent. RESULTS: By long-term follow-up of 13 patients, there was a statistically significant improvement in their YGTSS compared with preoperative rates (p<0.05< span="">). The mean improvement rate of patients’ TSQOL was 45.7% (improvement range was 11.0-77.2%), with a statistically significant improvement in quality of life compared with preoperative (p<0.05< span="">). CONCLUSION: GPi-DBS is an effective treatment for drug-refractory Tourette’s syndrome, which can improve symptoms and quality of life. This is the largest group of case reports in China applying DBS for the treatment of Tourette’s syndrome.